Humana Surpasses Earnings Expectations
Humana (NYSE:HUM) has published its third-quarter financial results, showcasing a profit and revenue that surpassed predictions. This positive shift is encouraging, particularly after the recent hurdles faced by the health insurance company.
Recent Rating Developments
Earlier this month, the company’s stock experienced a decline after the U.S. government revealed the quality ratings for the 2025 Medicare health and prescription drug plans. The new data indicated that only 25% of Humana’s members enrolled in plans that received ratings of 4 stars or above for 2025, a stark drop from 94% in the previous year.
Factors Behind the Rating Drop
Much of this decline can be attributed to the downgrade of Humana's H5216 contract, which fell from 4.5 stars to 3.5 stars. This significant change is expected to affect the quality bonus payments Humana may receive in 2026. The Centers for Medicare and Medicaid traditionally grant bonuses to health plans achieving ratings of 4 stars or higher, so this change will have important financial implications for the company.
Litigation Considerations
Industry analysts have noted that legal action could be on the horizon for Humana as the company considers overturning certain results related to these ratings. In response, Humana is actively taking measures to lessen the anticipated negative impact on its 2026 revenue, although it reassured stakeholders that this ratings drop would not change its financial outlook for 2024 or the current year.
Updated Financial Forecast
On a brighter note, Humana recently revised its predictions for individual Medicare Advantage membership growth for 2024, increasing it by approximately 5% to an estimated 265,000 members. The company also raised its full-year adjusted earnings per share guidance to at least $16, improving upon its earlier estimate of approximately $16.
Strong Q3 Performance
In the quarter ending September 30, Humana posted an adjusted income per share of $4.16, significantly exceeding the market consensus of $3.35. Additionally, the company’s revenue of $29.40 billion also outperformed expectations. According to statements from company executives, this success was largely driven by slightly higher-than-expected individual Medicare Advantage memberships and superior performance at its CenterWell primary care centers.
Industry Cost Expectations
The executives highlighted that their proactive approach in anticipating higher industry costs contributed to the positive results, as many patients are opting for elective surgeries that were postponed during the COVID-19 pandemic.
Consequently, shares of Humana saw an uptick in early U.S. trading, reflecting positive investor sentiment regarding the company's performance amidst the challenges it faces in the healthcare landscape.
Frequently Asked Questions
What were Humana's earnings for the third quarter?
Humana reported an adjusted income per share of $4.16 for the third quarter, surpassing consensus projections of $3.35.
How did Humana's revenue perform in Q3?
The company achieved a revenue of $29.40 billion, which exceeded market expectations.
What factors caused Humana's rating decline?
The drop in ratings was mainly due to the downgrade of Humana's H5216 contract from 4.5 stars to 3.5 stars.
What steps is Humana taking regarding their ratings?
Humana is considering legal options to challenge the ratings and is also taking measures to mitigate the anticipated revenue impact.
What does the future look like for Humana?
Humana has raised its forecast for membership growth in Medicare Advantage for 2024 and provided a positive earnings outlook despite recent quality rating challenges.
